Sho Masayuki, Murakami Yoshiaki, Motoi Fuyuhiko, Satoi Sohei, Matsumoto Ippei, Kawai Manabu, Honda Goro, Uemura Kenichiro, Yanagimoto Hiroaki, Kurata Masanao, Fukumoto Takumi, Akahori Takahiro, Kinoshita Shoichi, Nagai Minako, Nishiwada Satoshi, Unno Michiaki, Yamaue Hiroki, Nakajima Yoshiyuki
Department of Surgery, Nara Medical University, 840 Shijo-cho, Kashihara, Nara, 634-8522, Japan,
J Gastroenterol. 2015 Jun;50(6):694-702. doi: 10.1007/s00535-014-1005-4. Epub 2014 Oct 24.
The prognosis of pancreatic cancer patients with metastatic para-aortic lymph node (PALN) has been reported to be extremely poor. In general, PALN metastasis has been considered as a contraindication for pancreatic resection. The aim of this study was to reevaluate the postoperative prognostic value of PALN metastasis in pancreatic cancer and to determine the validity of pancreatic surgery.
Retrospective multicenter analysis of 882 patients who have undergone curative-intent pancreatic resection with pathological evaluation of PALNs for pancreatic ductal adenocarcinoma between 2001 and 2012 was conducted. Clinicopathological data and outcomes were evaluated with univariate and multivariate analysis.
In total, 102 (12.4 %) patients had positive metastasis in PALN. Patients with metastatic PALN had significantly poorer survival than those without (17 vs. 23 months; p < 0.001). Multivariable analysis of 822 patients identified adjuvant chemotherapy, primary tumor status, regional lymph node metastasis, portal vein invasion, pre- and post-operative serum CA19-9 levels, and tumor grade as independent prognostic factors. In contrast, PALN metastasis did not have a significant prognostic value. Furthermore, the multivariate prognostic analysis in patients with PALN metastasis revealed that adjuvant chemotherapy and the number of metastatic PALN were significantly associated with long-term survival. Lung metastasis as initial recurrence was observed more often in patients with PALN metastasis in comparison with those without.
Some pancreatic cancer patients with metastatic PALN may survive for longer than expected after pancreatectomy. Adjuvant chemotherapy and the number of metastatic PALN were critical factors for long-term survival of those patients.
据报道,伴有转移性主动脉旁淋巴结(PALN)的胰腺癌患者预后极差。一般而言,PALN转移被视为胰腺癌切除的禁忌证。本研究的目的是重新评估PALN转移在胰腺癌中的术后预后价值,并确定胰腺癌手术的有效性。
对2001年至2012年间接受根治性意图胰腺癌切除术并对PALN进行病理评估的882例胰腺导管腺癌患者进行回顾性多中心分析。通过单因素和多因素分析评估临床病理数据和结果。
总共有102例(12.4%)患者PALN转移呈阳性。伴有PALN转移的患者生存率明显低于无转移者(17个月对23个月;p<0.001)。对822例患者的多变量分析确定辅助化疗、原发肿瘤状态、区域淋巴结转移、门静脉侵犯、术前和术后血清CA19-9水平以及肿瘤分级为独立预后因素。相比之下,PALN转移没有显著的预后价值。此外,对PALN转移患者的多变量预后分析显示,辅助化疗和转移的PALN数量与长期生存显著相关。与无PALN转移的患者相比,PALN转移患者更常观察到以肺转移作为初始复发。
一些伴有PALN转移的胰腺癌患者在胰腺切除术后可能存活时间超过预期。辅助化疗和转移的PALN数量是这些患者长期生存的关键因素。